Genetic profiling of BRAF inhibitor-induced keratoacanthomas reveals no induction of MAP kinase pathway expression

J Invest Dermatol. 2013 Mar;133(3):830-833. doi: 10.1038/jid.2012.353. Epub 2012 Sep 27.

Authors

Rajan P Kulkarni¹, Seema Plaisier², Seong H Ra³, Xinmin Li³, Delphine J Lee², Joseph D Hillman³, Scott W Binder³

Affiliations

¹ Division of Dermatology, UCLA Medical Center, Los Angeles, California, USA. Electronic address: rkulkarn@ucla.edu.
² Department of Translational Immunology, Dirks/Dougherty Laboratory for Cancer Research, John Wayne Cancer Institute, Santa Monica, California, USA.
³ Department of Pathology, UCLA Medical Center, Los Angeles, California, USA.

PMID: 23014342
DOI: 10.1038/jid.2012.353

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biopsy
Gene Expression Profiling*
Gene Expression Regulation / drug effects
Humans
Indoles / adverse effects*
Indoles / pharmacology
Indoles / therapeutic use
Keratoacanthoma / chemically induced*
Keratoacanthoma / genetics
Keratoacanthoma / metabolism*
Melanoma / drug therapy
Mitogen-Activated Protein Kinase Kinases / genetics
Mitogen-Activated Protein Kinase Kinases / metabolism*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Retrospective Studies
Signal Transduction / genetics
Signal Transduction / physiology*
Skin / pathology
Skin Diseases / chemically induced
Skin Diseases / genetics
Skin Diseases / metabolism
Skin Neoplasms / drug therapy
Sulfonamides / adverse effects*
Sulfonamides / pharmacology
Sulfonamides / therapeutic use
Vemurafenib

Substances

Indoles
Sulfonamides
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinase Kinases